Education
About Us
Working with TipRanks
Follow Us
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (HK:2315)
:2315
RESEARCH TOOLSreports
Total Valuation
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H has a market cap or net worth of HK$8.73B. The enterprise value is HK$8.39B.
Market CapHK$8.73B
Enterprise ValueHK$8.39B
Share Statistics
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H has 110,781,920 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding110,781,920
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s return on equity (ROE) is 0.04 and return on invested capital (ROIC) is 6.09%.
Return on Equity (ROE)0.04
Return on Assets (ROA)0.01
Return on Invested Capital (ROIC)6.09%
Return on Capital Employed (ROCE)0.09
Revenue Per Employee877.76K
Profits Per Employee38.44K
Employee Count1,117
Asset Turnover0.41
Inventory Turnover2.11
Valuation Ratios
The current PE Ratio of Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H is 94.73. Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s PEG ratio is 0.70.
PE Ratio94.73
PS Ratio0.00
PB Ratio11.89
Price to Fair Value3.81
Price to FCF-25.06
Price to Operating Cash Flow-44.96
PEG Ratio0.70
Income Statement
In the last 12 months, Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H had revenue of 980.45M and earned 33.54M in profits. Earnings per share was 0.08.
Revenue980.45M
Gross Profit761.52M
Operating Income164.37M
Pretax Income42.94M
Net Income33.54M
EBITDA303.80M
Earnings Per Share (EPS)0.08
Cash Flow
In the last 12 months, operating cash flow was -29.47M and capital expenditures -58.81M, giving a free cash flow of -88.28M billion.
Operating Cash Flow-29.47M
Free Cash Flow-88.28M
Free Cash Flow per Share-0.80
Dividends & Yields
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.27
52-Week Price Change193.72%
50-Day Moving Average14.99
200-Day Moving Average9.91
Relative Strength Index (RSI)69.96
Average Volume (3m)378.33K
Important Dates
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H upcoming earnings date is Sep 2, 2025, TBA Not Confirmed.
Last Earnings DateMar 26, 2025
Next Earnings DateSep 2, 2025
Ex-Dividend Date―
Financial Position
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H as a current ratio of 1.53, with Debt / Equity ratio of 36.23%
Current Ratio1.53
Quick Ratio1.33
Debt to Market Cap0.13
Net Debt to EBITDA0.62
Interest Coverage Ratio1.79
Taxes
In the past 12 months, Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H has paid 9.40M in taxes.
Income Tax9.40M
Effective Tax Rate0.22
Enterprise Valuation
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H EV to EBITDA ratio is 11.08, with an EV/FCF ratio of 19.33.
EV to Sales3.43
EV to EBITDA11.08
EV to Free Cash Flow19.33
EV to Operating Cash Flow15.94
Balance Sheet
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H has HK$424.07M in cash and marketable securities with ¥575.25M in debt, giving a net cash position of HK$151.17M billion.
Cash & Marketable SecuritiesHK$424.07M
Total Debt¥575.25M
Net CashHK$151.17M
Net Cash Per ShareHK$1.36
Tangible Book Value Per ShareHK$2.06
Margins
Gross margin is 73.38%, with operating margin of 16.76%, and net profit margin of 3.42%.
Gross Margin73.38%
Operating Margin16.76%
Pretax Margin4.38%
Net Profit Margin3.42%
EBITDA Margin30.99%
EBIT Margin13.73%
Analyst Forecast
The average price target for Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast34.39%
EPS Growth Forecast―